Glucotrack reports full year 2024 financial results and recent corporate highlights

Transformational 2024: successfully advanced from preclinical to clinical stage company strengthened leadership team to drive growth and advance clinical development investigational device exemption (ide) approval for continuous blood glucose monitoring (cbgm) technology from fda expected in q4 2025 rutherford, nj, march 31, 2025 (globe newswire) -- glucotrack, inc. (nasdaq: gctk) (“glucotrack” or the “company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended december 31, 2024. “2024 was transformative for glucotrack as we advanced the development of our cbgm technology and successfully transitioned from a preclinical to a clinical stage company.
GCTK Ratings Summary
GCTK Quant Ranking